See more : Artemis Strategic Investment Corporation (ARTE) Income Statement Analysis – Financial Results
Complete financial analysis of Novan, Inc. (NOVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novan, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Canadian Utilities Limited (CU.TO) Income Statement Analysis – Financial Results
- China Science Publishing & Media Ltd. (601858.SS) Income Statement Analysis – Financial Results
- TORICO Co., Ltd. (7138.T) Income Statement Analysis – Financial Results
- Hangzhou Chuhuan Science & Technology Company Limited (001336.SZ) Income Statement Analysis – Financial Results
- Buru Energy Limited (BRNGF) Income Statement Analysis – Financial Results
Novan, Inc. (NOVN)
About Novan, Inc.
Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.61M | 2.82M | 4.21M | 4.48M | 5.99M | 2.14M | 0.00 | 0.00 | 112.00K |
| Cost of Revenue | 7.38M | 0.00 | 0.00 | 25.17M | 23.05M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 16.23M | 2.82M | 4.21M | -20.70M | -17.05M | 2.14M | 0.00 | 0.00 | 112.00K |
| Gross Profit Ratio | 68.74% | 100.00% | 100.00% | -462.25% | -284.66% | 100.00% | 0.00% | 0.00% | 100.00% |
| Research & Development | 15.99M | 20.42M | 19.81M | 25.17M | 23.05M | 25.21M | 46.49M | 16.57M | 6.77M |
| General & Administrative | 0.00 | 12.34M | 11.27M | 10.41M | 11.51M | 0.00 | 13.34M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 34.10M | 12.34M | 11.27M | 10.41M | 11.51M | 13.11M | 13.34M | 9.27M | 5.17M |
| Other Expenses | 1.53M | -136.00K | -712.00K | -419.00K | 72.00K | 0.00 | 127.00K | 0.00 | 0.00 |
| Operating Expenses | 51.62M | 32.62M | 30.37M | 35.17M | 34.55M | 38.33M | 59.83M | 25.83M | 11.94M |
| Cost & Expenses | 59.00M | 32.62M | 30.37M | 35.17M | 34.55M | 38.33M | 59.83M | 25.83M | 11.94M |
| Interest Income | 53.00K | 13.00K | 51.00K | 177.00K | 297.00K | 0.00 | 81.00K | 48.00K | 58.00K |
| Interest Expense | 1.45M | 0.00 | 0.00 | 2.00K | 1.05M | 0.00 | 2.00K | 1.00K | 701.00K |
| Depreciation & Amortization | 1.63M | -384.00K | 6.14M | 2.35M | 1.66M | 1.42M | 757.00K | 631.00K | 462.00K |
| EBITDA | -33.76M | -30.30M | -24.07M | -28.34M | -26.53M | -33.82M | -59.83M | -25.16M | -11.31M |
| EBITDA Ratio | -142.99% | -1,073.67% | -572.10% | -633.06% | -442.80% | -1,580.37% | 0.00% | 0.00% | -10,096.43% |
| Operating Income | -35.39M | -29.92M | -30.21M | -30.69M | -28.56M | -36.19M | -59.83M | -25.83M | -11.83M |
| Operating Income Ratio | -149.90% | -1,060.06% | -718.01% | -685.46% | -476.73% | -1,690.89% | 0.00% | 0.00% | -10,560.71% |
| Total Other Income/Expenses | 4.08M | 223.00K | 921.00K | 47.00K | 0.00 | -942.00K | 127.00K | 48.00K | -1.28M |
| Income Before Tax | -31.31M | -29.69M | -29.29M | -30.64M | -12.67M | -37.13M | -59.70M | -25.79M | -13.10M |
| Income Before Tax Ratio | -132.62% | -1,052.16% | -696.13% | -684.41% | -211.53% | -1,734.91% | 0.00% | 0.00% | -11,699.11% |
| Income Tax Expense | -11.75M | -855.00K | 870.00K | 138.00K | -15.89M | 942.00K | -757.00K | 2.28M | -1.01M |
| Net Income | -19.56M | -28.84M | -30.16M | -30.78M | -12.67M | -37.13M | -59.70M | -28.06M | -11.39M |
| Net Income Ratio | -82.85% | -1,021.86% | -716.80% | -687.49% | -211.53% | -1,734.91% | 0.00% | 0.00% | -10,167.86% |
| EPS | -0.89 | -1.69 | -3.05 | -11.72 | -4.91 | -23.23 | -99.73 | -25.11 | -10.19 |
| EPS Diluted | -0.89 | -1.69 | -3.05 | -11.72 | -4.91 | -23.23 | -99.73 | -25.11 | -10.19 |
| Weighted Avg Shares Out | 22.02M | 17.07M | 9.88M | 2.63M | 2.58M | 1.60M | 598.60K | 1.12M | 1.12M |
| Weighted Avg Shares Out (Dil) | 22.02M | 17.07M | 9.88M | 2.63M | 2.58M | 1.60M | 598.60K | 1.12M | 1.12M |
Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
Novan, Inc. (NOVN) Q1 2023 Earnings Call Transcript
Novan to Report First Quarter 2023 Financial Results on May 15, 2023
Novan to Report Full Year 2022 Financial Results on March 30, 2023
Novan to Present at the Oppenheimer 33rd Annual Healthcare Conference
Novan to Present at the Virtual Investor 2023 Companies to Watch Event
Ligand's Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
Novan, Inc. (NOVN) Q3 2022 Earnings Call Transcript
Novan, Inc. (NOVN) CEO Paula Stafford on Q2 2022 Results - Earnings Call Transcript
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022
Source: https://incomestatements.info
Category: Stock Reports